Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia

Published:2019-04-17 Issue: Volume: Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Croteau Stacy E.¹^ORCID,Cheng Dunlei²,Cohen Alice J.³,Holmes Chris E.⁴,Malec Lynn M.⁵^ORCID,Silvey Michael⁶,Thornburg Courtney D.⁷^ORCID,Wheeler Allison P.⁸,Kouides Peter A.⁹,Raffini Leslie J.¹⁰,Neufeld Ellis J.¹¹

Affiliation:

1. Boston Children's Hospital Boston Massachusetts

2. American Thrombosis and Hemostasis Network Rochester New York

3. Newark Beth Israel Medical Center Newark New Jersey

4. University of Vermont Burlington Vermont

5. Versiti Blood Center of Wisconsin Milwaukee Wisconsin

6. Children’s Mercy Hospital Kansas City Missouri

7. Rady Children's Hospital San Diego San Diego California

8. Monroe Carell Jr. Children’s Hospital at Vanderbilt Nashville Tennessee

9. Mary M. Gooley Hemophilia Center Rochester New York

10. Children's Hospital of Philadelphia Philadelphia Pennsylvania

11. St. Jude Children's Research Hospital Memphis Tennessee

Funder

Hemostasis and Thrombosis Research Society

Hemophilia of Georgia

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13758

Reference22 articles.

1. 2017 Clinical trials update: Innovations in hemophilia therapy;Hartmann J;Am J Hematol,2016

2. Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia;Mahdi AJ;Br J Haematol,2015

3. The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO;Collins P;Haemophilia,2016

4. Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII;Hermans C;Haemophilia,2018

5. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc;Berntorp E;Haemophilia,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data;Journal of Medical Economics;2023-10-25

2. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half‐life (EHL) factor products: A 12‐month data analysis;Haemophilia;2023-08-11

3. Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018–2020);Thrombosis Research;2023-07

4. Health care costs and resource use of managing hemophilia A: A targeted literature review;Journal of Managed Care & Specialty Pharmacy;2023-06

5. Cross-sectional analysis of Open payments for physicians at designated hemophilia centers in the US (2018-2020);2023-03-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3